abil
dendrit
cell
dc
orchestr
innat
adapt
immun
respons
exploit
develop
potent
anticanc
immunotherapi
recent
clinic
trial
explor
efficaci
ex
vivo
modifi
autolog
dcbase
vaccin
report
promis
result
howev
vitro
gener
autolog
dc
clinic
administr
load
tumor
associ
antigen
taa
activ
labori
expens
due
interindividu
variabl
person
vaccin
poorli
standard
attract
altern
approach
load
resid
dc
vivo
target
deliveri
taa
use
viral
vector
activ
simultan
end
construct
genet
modifi
adenovir
ad
vector
bispecif
adaptor
molecul
retarget
ad
vector
encod
taa
receptor
dc
preclin
human
murin
studi
conduct
far
clearli
demonstr
suitabl
twocompon
ie
ad
adaptor
molecul
configur
target
modif
dc
vivo
cancer
immunotherapi
review
summar
recent
progress
develop
adbas
cancer
vaccin
highlight
preclin
issu
clinic
translat
approach
dendrit
cell
dc
key
orchestr
adapt
immun
system
dc
outstand
abil
captur
process
present
antigen
activ
naiv
cell
also
abil
regul
natur
cell
respons
provid
appropri
costimulatori
signal
dictat
either
immunogen
tolerogen
cell
stimul
uniqu
featur
make
target
manipul
dc
attract
approach
modul
immun
respons
cancer
ex
vivo
modifi
dcbase
vaccin
use
clinic
immunotherapi
cancer
far
limit
success
review
product
dc
vaccin
usual
entail
differenti
dc
individu
patient
progenitor
cell
subsequ
load
tumorassoci
antigen
taa
follow
appropri
matur
induct
inject
back
patient
hope
induc
effect
antitumor
immun
respons
limit
clinic
efficaci
observ
far
may
due
suboptim
ex
vivo
dc
activationmatur
requir
effect
teffector
cell
prime
differenti
limit
migrat
administ
dc
typic
less
inject
dc
number
reach
vaccin
sitedrain
lymph
node
ln
cell
activ
occur
even
though
optim
may
expect
enhanc
efficaci
dc
vaccin
approach
remain
labori
expens
moreov
interindividu
variabl
qualiti
vaccin
inher
autolog
cellbas
approach
complic
interpret
clinic
data
attract
altern
approach
load
resid
dc
vivo
target
deliveri
taa
activ
simultan
therebi
avoid
cumbersom
isol
cultur
dc
precursor
cell
also
serv
exploit
natur
home
abil
ln
activ
dc
situ
effect
antigen
specif
cell
activ
outcom
immun
respons
induc
target
antigen
dc
depend
mani
factor
includ
specif
receptor
target
express
level
target
receptor
distribut
among
differ
dc
subset
presenc
absenc
coadminist
adjuv
antigen
deliveri
system
use
specif
receptor
choic
follow
characterist
target
select
highli
express
dc
target
antigen
effect
intern
process
present
antigen
specif
cell
ideal
thelper
cell
th
cytotox
lymphocyt
ctl
target
deliveri
antigen
prefer
lead
select
activ
target
dc
bypass
need
coadministr
adjuv
induc
optim
antitumor
immun
respons
varieti
receptor
express
dc
exploit
target
antigen
dc
vivo
includ
mhc
ii
receptor
cire
mannos
receptor
mr
configur
use
target
deliveri
antigen
vivo
includ
peptid
protein
conjug
receptor
ligand
monoclon
antibodi
specif
receptor
express
dc
surfac
microor
nanoparticl
load
coat
peptid
viral
nonvir
vector
carri
taa
encod
gene
among
system
natur
abil
viral
vector
effici
infect
target
cell
util
cellular
machineri
product
viral
encod
antigen
make
attract
vaccin
vehicl
addit
viral
vector
also
effect
mimic
natur
infect
trigger
right
kind
innat
immun
respons
precondit
develop
effect
respons
vaccineencod
antigen
virus
even
exhibit
natur
tropism
dc
make
preemin
suitabl
vaccin
carrier
dctarget
vaccin
final
viral
transduct
result
durabl
endogen
antigen
express
facilit
mhc
class
present
proteasomemedi
degrad
also
continu
present
antigen
specif
ctl
prolong
period
time
henc
make
attenu
nonrepl
virus
attract
vaccin
carrier
cancer
immunotherapi
contrast
nonvir
system
often
need
specif
design
optim
achiev
list
advantag
natur
trait
viral
vector
adenovir
ad
vector
sever
characterist
make
particularli
use
vehicl
dctarget
gene
deliveri
nonenvelop
virus
stabli
packag
lyophil
prepar
vial
capsul
ad
dna
integr
host
chromosom
dna
admedi
transduct
thu
pose
minim
risk
insert
mutagenesi
ad
vector
easili
grown
high
titer
exhibit
low
cytotox
larg
clone
capac
effici
gene
transfer
even
nondivid
target
cell
latter
particular
relev
dc
target
dc
resid
peripher
tissu
reach
endstag
differenti
lost
prolif
capac
commonli
use
vector
deriv
ad
shown
potenti
stimul
potent
humor
cellular
immun
respons
transgen
encod
antigen
notabl
toxic
reduc
efficaci
associ
preexist
immun
common
ad
vector
infect
human
review
ad
vectorbas
vaccin
therapeut
still
consid
among
safest
effect
lead
continu
applic
develop
improv
treatment
divers
array
diseas
except
abil
ad
vector
gener
cellular
immun
recombin
antigen
human
make
prefer
antigen
carrier
cancer
vaccin
mani
tumor
cell
express
antigen
provid
potenti
target
therapeut
vaccin
strategi
boost
natur
immunemedi
tumor
reject
identif
character
gene
encod
cancer
reject
antigen
open
new
way
develop
cancer
vaccin
mani
recombin
ad
vector
encod
taa
gener
cancer
immunotherapi
purpos
limit
clinic
experi
shown
recombin
ad
vaccin
cancer
patient
safe
though
convinc
evid
clinic
efficaci
still
lack
fiber
knob
domain
mediat
bind
coxsackieadenoviru
receptor
car
target
cell
surfac
cell
see
fig
subsequ
interact
ad
penton
base
ie
protrud
fiber
connect
viral
capsid
integrin
cell
surfac
facilit
intern
virion
howev
dc
resist
infect
due
lack
express
primari
dock
receptor
car
present
challeng
effect
transduct
dc
ad
direct
vivo
administr
untarget
may
thu
result
cytopath
effect
due
ectop
gene
transfer
car
express
bystand
cell
rather
dc
moreov
subsequ
antigen
present
transduc
nonprofession
antigenpres
cell
apc
may
lead
suboptim
cell
activ
even
toler
induct
system
util
vector
also
limit
result
high
preval
popul
preexist
immun
toward
vector
preexist
immun
may
also
limit
vaccin
efficaci
vector
primeboost
protocol
avoid
side
effect
improv
therapeut
efficaci
natur
tropism
vector
ablat
alter
improv
select
tropism
dc
gener
either
twocompon
singlecompon
approach
use
achiev
goal
fig
twocompon
approach
bispecif
adaptor
molecul
complex
ad
vector
simultan
block
nativ
receptor
bind
retarget
ad
vector
receptor
express
target
cell
interest
singlecompon
approach
ad
vector
genet
modifi
ablat
nativ
receptor
bind
retarget
vector
cell
receptor
interest
main
advantag
twocompon
approach
great
flexibl
sinc
vector
carri
differ
gene
interest
easili
coupl
adaptor
hand
singlecompon
system
offer
advantag
standard
manufactur
provid
greater
potenti
commerci
distribut
therapeut
vector
explor
approach
retarget
vector
surfac
receptor
skin
dc
endeavor
translat
intraderm
id
dctarget
vaccin
approach
clinic
fig
cell
surfac
receptor
belong
tumor
necrosi
factorreceptor
tnfr
famili
first
identifi
function
character
b
lymphocyt
later
report
reveal
express
restrict
b
cell
also
express
monocyt
dc
nonhematopoiet
cell
includ
keratinocyt
fibroblast
neuron
endotheli
epitheli
tumor
cell
receptor
dc
play
crucial
role
matur
cell
fulli
compet
antigen
present
cell
gener
longterm
effector
cell
mediat
immun
interact
receptor
b
cell
critic
induct
humor
immun
respons
promot
prolifer
differenti
b
cell
immunoglobulin
produc
plasma
cell
nonhematopoiet
cell
endotheli
cell
involv
amplif
regul
inflammatori
respons
normal
cell
respons
dc
engag
transient
express
activ
th
cell
interact
import
activ
dc
normal
well
regulatori
cell
treg
induc
suppress
condit
import
dc
activ
via
ligat
demonstr
number
studi
dc
target
antibodyantigen
fusion
product
induc
toler
antigen
unless
agonist
mab
coadminist
henc
agonist
mab
recombin
trimer
administ
combin
antigen
induc
memori
protect
cell
respons
other
pursu
strategi
combin
antigen
deliveri
dc
simultan
activ
although
express
restrict
dc
dc
activ
properti
nevertheless
make
attract
target
motif
moreov
rout
administr
may
determin
whether
rel
overexpress
dc
provid
enough
window
achiev
select
target
data
human
skin
human
skindrain
ln
certainli
indic
case
id
rout
administr
clearli
demonstr
bind
might
occur
cell
eg
endotheli
cell
dermi
b
cell
ln
interfer
effici
vaccin
deliveri
dc
subsequ
ctl
activ
note
express
dc
target
motif
pursu
vaccin
purpos
often
also
restrict
dc
case
point
dcsign
confirm
express
macrophag
human
ln
despit
often
perceiv
expound
specif
dc
also
mani
altern
target
includ
dcsign
lack
ad
advantag
mediat
dc
activ
therefor
other
design
test
vaccin
construct
agonist
bind
target
deliveri
antigen
dc
simultan
matur
induct
two
igbas
vaccin
construct
design
schjetn
et
al
agonist
target
multipl
myeloma
b
cell
lymphoma
antigen
receptor
murin
apc
first
construct
consist
recombin
mab
v
region
specif
c
region
contain
defin
cell
epitop
homodim
chain
compos
singlechain
variabl
region
fragment
scfv
target
dimer
motif
antigen
unit
construct
bound
induc
matur
dc
enhanc
primari
memori
cell
respons
intramuscular
deliveri
vaccin
construct
form
nake
dna
induc
cell
respons
specif
mhc
class
iirestrict
epitop
antibodi
respons
protect
mice
myeloma
lymphoma
growth
observ
effect
attribut
target
deliveri
antigen
apc
present
mhc
class
ii
molecul
simultan
activ
target
apc
sinc
ctl
abil
specif
recogn
kill
tumor
cell
recent
effort
develop
anticanc
vaccin
mainli
focus
enhanc
induct
tumorspecif
lymphocyt
respons
achiev
deliveri
vector
dc
situ
past
decad
explor
differ
configur
efficaci
term
situ
dc
target
transduct
subsequ
cell
activ
tumor
protect
fig
next
paragraph
differ
configur
describ
preclin
evid
efficaci
discuss
highlight
pro
con
clinic
translat
togeth
observ
illustr
preclin
triumph
failur
line
long
wind
road
clinic
translat
first
prepar
test
chemic
conjug
bispecif
antibodi
construct
consist
fab
fragment
bind
fiber
knob
neutral
fashion
agonist
bind
mab
retarget
use
bispecif
antibodi
construct
dramat
enhanc
gene
transfer
monocyt
deriv
dc
modc
also
induc
phenotyp
function
matur
first
studi
function
activ
evidenc
increas
cell
stimul
allogen
mix
leukocyt
reaction
mlr
enhanc
releas
use
chemic
ab
conjug
incorpor
murin
target
mab
found
particular
target
approach
also
significantli
enhanc
gene
transfer
induc
phenotyp
matur
murin
bone
marrowderiv
dc
bmdc
subcutan
sc
inject
bmdc
transduc
vector
encod
viral
oncogen
deriv
human
papillomaviru
hpv
result
superior
protect
outgrowth
tumor
cell
vivo
note
protect
shown
depend
cell
demonstr
clinic
util
vector
deem
essenti
assess
perform
context
human
tissu
test
dc
target
abil
physiolog
clinic
highli
relev
circumst
therefor
demonstr
util
approach
situ
gene
transfer
dc
id
inject
employ
bispecif
mab
conjug
human
skin
explant
model
fig
target
vector
enhanc
select
transduct
human
dc
locat
dermi
cultur
skin
explant
also
increas
stabil
matur
statu
upon
migrat
inde
observ
follow
id
deliveri
skin
explant
tissu
absolut
number
egfp
transduc
dc
present
migratori
popul
significantli
increas
fig
importantli
transduc
phenotyp
matur
ie
activ
dc
demonstr
superior
capac
stimul
antigenspecif
memori
cell
employ
haeminfluenza
matrix
protein
model
antigen
despit
promis
preclin
result
obtain
bispecif
antibodybas
target
approach
clinic
translat
imped
inher
variabl
chemic
antibodi
conjug
process
result
low
yield
function
activ
bispecif
molecul
overcom
limit
construct
welldefin
molecular
fusion
protein
solubl
car
scar
scfv
mab
bind
neutral
fiber
knob
car
portion
fusion
protein
agonist
bind
scfv
significantli
enhanc
transduct
dc
rhesu
monkey
human
origin
achiev
similarli
bispecif
scfv
fusion
protein
construct
cdna
antiad
fiber
knob
scfv
scfv
retarget
ad
vector
use
bispecif
scfv
fusion
protein
significantli
enhanc
transduct
effici
modc
also
abil
function
activ
haeminfluenza
specif
memori
cell
isol
peripher
blood
healthi
donor
despit
proven
function
clinic
develop
molecular
fusion
protein
abandon
gener
consensu
time
rapid
clinic
translat
requir
clean
singlecompon
vaccin
would
greatli
simplifi
qualiti
assurancequ
control
qaqc
criteria
vaccin
product
accord
clinicalgrad
good
manufactur
practic
cgmp
moreov
also
believ
facilit
safeti
assess
singl
phasei
clinic
trial
singlecompon
adbas
dctarget
vaccin
requir
largescal
product
genet
alter
ad
vector
ablat
natur
tropism
consist
retarget
fiber
prove
consider
technic
challeng
earli
effort
genet
retarget
ad
vector
mostli
focus
alter
tropism
viru
incorpor
target
receptorspecif
ligand
either
carboxi
terminu
hi
loop
fiber
site
toler
insert
small
linear
ligand
sequenc
without
substanti
affect
infect
propag
result
retarget
vector
insert
complex
fold
consequ
select
ligand
appear
disturb
trimer
ad
fiber
prevent
subsequ
incorpor
fiber
adenoviru
capsid
overcom
limit
fiber
replac
strategi
gener
tropismmodifi
consid
strategi
fiber
knob
domain
alon
togeth
shaft
domain
replac
combin
two
heterolog
domain
one
function
receptorbind
ligand
support
function
structur
entir
protein
chimera
show
feasibl
approach
replac
fiber
protein
protein
chimera
compris
ntermin
portion
fiber
genet
fuse
phage
fibritin
contain
trimer
motif
thu
facilit
natur
trimer
structur
fiber
fig
target
result
vector
artifici
receptor
achiev
incorpor
ctermin
peptid
ligand
protein
chimera
subsequ
use
strategi
creat
vector
retarget
human
incorpor
function
tnflike
domain
chimer
ad
fiber
consist
fiber
capsidanchor
nterminu
trimer
phage
fibritin
fig
despit
consider
size
domain
complex
tertiari
structur
compon
target
protein
domain
ff
backbon
fold
properli
therebi
make
entir
chimera
fulli
function
incorpor
chimer
fiber
ad
virion
affect
function
structur
compon
result
vector
use
surrog
receptor
cell
entri
howev
compar
ad
untarget
ad
contain
wildtyp
wt
fiber
ad
show
significantli
reduc
transduct
effici
target
cell
express
car
high
level
experi
radiolabel
ad
untarget
ad
nevertheless
reveal
virus
equal
effici
bind
target
cell
result
led
us
hypothes
complet
delet
fiber
ad
affect
abil
infect
target
cell
interf
downstream
process
primari
bind
cell
surfac
construct
mosaic
version
ad
addit
phage
fibritin
human
chimer
fiber
also
contain
full
size
wt
fiber
engin
lack
carbind
abil
delet
carbind
tayt
sequenc
enhanc
abil
infect
target
cell
facilit
larg
scale
product
stabli
vector
ie
subsequ
comparison
mosaic
ad
untarget
show
superior
transduct
efficaci
mosaic
vector
human
modc
vitro
determin
potenti
vector
effect
situ
target
antigen
express
dc
construct
mosaic
ad
encod
gfp
carcinoembryon
antigen
cea
applic
vector
stringent
human
skin
explant
model
demonstr
util
vivo
select
transduct
dc
induct
activ
migrat
grant
propos
subsequ
submit
nihrapid
applic
innov
drug
raid
programm
support
cgmp
product
vector
without
egfp
sequenc
safeti
feasibl
test
phasei
clinic
trial
patient
advanc
colon
cancer
although
propos
receiv
favor
review
deem
scientif
fundabl
nih
biolog
resourc
branch
oversight
committe
insist
remov
dtayt
fiber
mosaic
construct
ratio
incorpor
fiber
could
control
product
process
therebi
complic
standard
qualiti
control
final
product
poor
perform
subsequ
construct
vector
human
skin
explant
model
coupl
cgmp
upscal
issu
involv
initi
wt
fiber
complement
twotier
system
vector
propag
product
ultim
preclud
clinic
develop
chimer
ad
vector
final
attempt
circumv
need
wt
fiber
complement
product
retarget
ad
vector
explor
new
strategi
base
replac
ad
fiber
molecul
reoviru
chimer
attach
protein
consist
ntermin
domain
ad
fiber
fuse
ii
domain
proper
trimer
incorpor
human
target
moieti
construct
express
plasmid
encod
fusion
protein
ad
tail
ii
domain
link
human
upon
express
chimer
attach
protein
effici
trimer
retain
capac
specif
bind
moreov
reconstitut
fulli
function
infecti
viral
particl
observ
upon
transfect
fiber
contain
doubli
ablat
genom
ie
delet
carand
integrinbind
sequenc
unpublish
data
nevertheless
approach
would
still
requir
cgmp
develop
cell
line
clinicalgrad
propag
largescal
product
ad
vector
deem
costinhibit
extent
would
preclud
clinic
translat
within
forese
futur
approach
abandon
fact
differ
attitud
gain
upper
hand
field
translat
cancer
studi
favor
acceler
clinic
test
combin
therapi
thu
gener
renew
interest
twocompon
approach
ad
vaccin
ad
vector
bind
car
via
knob
domain
fiber
protein
three
car
molecul
bind
per
fiber
knob
base
understand
develop
novel
carcontain
adaptor
molecul
assum
trimer
conform
via
trimer
motif
deriv
acid
fragment
bacteriophag
fibritin
protein
trimer
structur
car
result
effici
bind
neutral
fiber
knob
order
facilit
effici
transduct
activ
murin
dc
design
produc
recombin
fusion
protein
contain
ectodomain
car
genet
link
via
trimer
motif
extracellular
domain
mous
incorpor
trimer
motif
serv
two
purpos
increas
ad
fiber
knob
bind
avid
promot
stabil
nativ
trimer
conform
necessari
effici
bind
function
adaptor
produc
mammalian
cell
benefit
posttransl
glycosyl
produc
adaptor
demonstr
strong
affin
fiber
knob
mous
human
use
retarget
enhanc
transduct
activ
murin
human
dc
compat
explain
high
homolog
incorpor
murin
tnflike
domain
human
counterpart
subcutan
inject
configur
encod
model
antigen
induc
superior
antigenspecif
th
ctl
respons
balbc
mice
id
inject
encod
sarscov
np
result
antigenspecif
immun
respons
balb
c
infecti
mous
model
similarli
stronger
cell
antibodi
respons
indic
skew
recent
observ
human
tumor
antigen
cea
upon
id
deliveri
vaccin
incorpor
domain
canin
model
obtain
definit
preclin
proofofconcept
configur
term
break
immun
toler
taa
therapeut
anticanc
efficaci
ex
vivo
human
ctl
prime
vivo
vaccin
studi
perform
size
approx
nm
predict
upon
id
deliveri
vaccin
target
dermal
locat
dc
also
rapidli
drain
lymphat
ln
target
lnresid
dc
subset
therefor
import
note
recent
studi
demonstr
enhanc
ex
vivo
transduct
convent
plasmacytoid
dc
subset
ad
use
adaptor
suspens
human
melanomadrain
sentinel
ln
sln
see
fig
moreov
target
encod
melanoma
taa
enhanc
expans
function
cell
sln
fig
concomit
decreas
cell
ratio
prolifer
rate
immunosuppress
hi
treg
addit
vitro
studi
reveal
transduct
activ
modc
significantli
enhanc
prime
effici
fulli
function
effector
ctl
respond
epitop
high
avid
importantli
prime
ctl
significantli
higher
avid
ctl
prime
peptideload
modc
effici
lyse
melanoma
cell
addit
recent
obtain
evid
id
deliveri
ad
vector
encod
full
length
melanoma
antigen
effici
induc
antigen
specif
ctl
mice
significantli
retard
subcutan
growth
highli
aggress
poorli
immunogen
murin
melanoma
therapeut
set
togeth
data
provid
clear
vitro
vivo
evid
enhanc
efficaci
ad
vaccin
encod
fulllength
tumor
antigen
target
adaptor
protein
dc
skin
skindrain
ln
aim
translat
approach
clinic
envis
approach
recruit
activ
langerhan
cell
lc
dermal
dc
skin
select
transduc
possibl
dc
resid
vaccin
sitedrain
ln
situ
target
ad
vector
encod
full
length
taa
would
result
clinic
applic
highli
flexibl
twocompon
dctarget
ad
vector
configur
allow
vaccin
differ
taa
encod
ad
vector
simultan
depend
antigen
express
profil
primari
metastat
tumor
vaccin
develop
preclin
studi
bridg
gap
design
candid
vaccin
clinic
develop
among
vast
number
preclin
model
avail
choos
right
model
evalu
efficaci
mode
action
candid
vaccin
alway
crucial
step
vaccin
develop
eventu
success
clinic
applic
case
ad
vaccin
develop
util
follow
model
system
vitro
human
murin
dc
cultur
model
human
fullthick
skin
explant
model
human
ex
vivo
melanomadrain
ln
model
vivo
murin
melanoma
infecti
model
vivo
canin
immun
model
model
allow
us
investig
key
immun
nonimmun
event
affect
mount
effect
antitumor
immun
respons
vivo
although
human
murin
vitro
dc
cultur
model
provid
easili
access
system
obtain
proof
principl
term
dc
transduct
activ
stringent
human
skin
explant
model
provid
clinic
relev
inform
perform
human
dctarget
vaccin
intact
tissu
context
furthermor
increas
appreci
speciesspecif
differ
dc
subset
activ
poor
crossprim
activ
murin
lc
contrast
superior
crossprim
induct
cell
human
lc
support
studi
util
human
skin
explant
model
select
effici
situ
lc
dermal
dc
transduct
ad
demonstr
organotyp
model
presenc
epiderm
dermal
cellular
matrix
compon
would
case
upon
vivo
dermal
deliveri
moreov
model
provid
vital
proof
increas
dc
matur
induct
function
dc
migrat
transgen
antigenspecif
cell
stimul
migrat
dc
upon
id
inject
ad
fig
b
event
vital
step
toward
effici
antitumor
cell
prime
ultim
clinic
efficaci
similarli
ex
vivo
suspens
melanoma
sln
util
demonstr
select
dc
transduct
ln
well
dc
matur
enhanc
activ
expans
taaspecif
cell
resid
sln
fig
togeth
two
human
ex
vivo
model
repres
two
vital
vivo
compart
immunolog
prime
instig
upon
id
deliveri
vaccin
skin
dc
dens
lymphat
network
drain
ln
migrat
dc
encount
naiv
cell
specif
cell
prime
expans
take
place
feel
human
organotypicex
vivo
model
vital
predict
target
viru
behav
tissu
microenviron
clinic
set
import
sinc
oftus
mous
model
differ
consider
human
skin
anatomi
cutan
lymphat
drainag
pattern
dc
subset
definit
instanc
contrast
human
skin
fail
demonstr
recruit
lc
dermal
dc
dermal
vaccin
site
murin
skin
pretreat
either
cytokin
eg
gmcsf
immunostimulatori
tlrl
eg
cpg
lp
hangalapura
et
al
unpublish
data
recruit
human
skin
provid
reservoir
migratori
lcdc
could
effici
target
intraderm
deliv
ad
much
thinner
murin
dermi
could
reproduc
observ
neither
ex
vivo
vivo
nevertheless
id
administr
ad
murin
melanoma
model
provid
evid
transduct
involv
skin
dc
observ
antitumor
respons
reveal
dc
target
vaccin
sitedrain
ln
fig
interestingli
id
inject
untarget
result
higher
total
transgen
express
level
ln
clear
sign
success
ablat
natur
tropism
upon
mostli
attribut
transduct
macrophagelik
cell
margin
sinus
fig
b
contrast
preferenti
transduc
dc
paracort
area
obvious
anatom
inform
could
obtain
transduct
experi
human
ex
vivo
slnderiv
singlecel
suspens
murin
vivo
data
also
reveal
effici
induct
taaspecif
ctl
prophylact
therapeut
antitumor
efficaci
ad
anatom
canin
skin
lymphat
close
resembl
human
skin
dog
may
therefor
provid
relev
transit
anim
model
preclin
valid
id
administ
dctarget
ad
vaccin
similarli
human
canin
rapidli
recruit
dc
myeloid
cell
dermi
local
site
id
inject
gmcsf
timar
et
al
unpublish
data
recent
show
util
canin
model
immunolog
efficaci
assess
id
inject
ad
vaccin
encod
taa
cea
target
vaccin
result
enhanc
prolif
serolog
respons
cea
addit
point
induct
skew
immun
respons
canin
tumor
histolog
molecular
makeup
biolog
behavior
close
resembl
human
tumor
sinc
dog
contrast
experiment
avail
mous
tumor
model
outbr
canin
tumor
model
may
provid
highli
relev
set
preclin
test
antitumor
efficaci
dctarget
vaccin
conclus
obtain
preclin
proof
efficaci
id
deliv
dctarget
vaccin
limit
murin
model
recogn
specif
differ
anatomi
dc
subset
definit
function
complementari
human
ex
vivo
model
relev
transitionaltransl
anim
model
eg
canin
therefor
also
consid
preclin
valid
see
ad
vaccin
provid
novel
approach
cancer
immunotherapi
convinc
evid
obtain
past
decad
number
ex
vivo
human
vivo
anim
model
see
comprehens
overview
show
efficaci
dctarget
vaccin
approach
term
immun
activ
tumor
protect
preclin
studi
thu
provid
strong
rational
clinic
applic
present
aim
produc
cgmpgrade
twocompon
configur
ie
encod
melanoma
antigen
adaptor
molecul
particular
configur
target
modif
dc
vivo
carri
sever
advantag
offer
great
flexibl
singlecompon
approach
ultim
enabl
select
vector
carri
specif
taa
gene
base
taa
express
profil
tumor
patient
vaccin
select
vector
complex
adaptor
molecul
prior
intraderm
inject
cgmp
grade
vector
encod
variou
clinic
relev
taa
prostat
specif
antigen
psa
alreadi
use
phase
iii
clinic
trial
demonstr
safe
make
obviou
candid
combin
adaptor
avail
cgmpgrade
vector
rel
easi
straightforward
procedur
associ
product
adaptor
protein
acceler
clinic
translat
approach
order
minim
presenc
either
free
adaptor
protein
noncomplex
vector
vaccin
prepar
potenti
result
poor
vaccin
efficaci
inadequ
activ
andor
transduct
dc
optim
adaptortovector
ratio
determin
care
crosstitr
test
transduct
effici
monocyt
deriv
dermal
sln
dc
importantli
vivo
biodistribut
antitumor
studi
clearli
demonstr
stabil
adaptorcomplex
vector
notabl
impress
ablat
natur
tropism
see
also
often
voic
concern
relat
vaccin
preexist
induc
specif
seroreact
might
neutral
viru
interfer
efficaci
regard
encourag
note
retain
abil
infect
human
dc
vitro
presenc
antibodi
moreov
led
induct
reduc
level
antibodi
vivo
ensur
longlast
cellmedi
respons
transgen
product
current
consid
vaccin
advancedstag
melanoma
patient
vector
encod
evalu
clinic
perform
smallscal
exploratori
phase
trial
human
microdos
studi
would
adher
fda
guidelin
investig
new
drug
ind
studi
releas
encod
ad
vector
alreadi
shown
clinic
safe
would
propos
administ
vector
id
configur
low
subtox
dose
eg
viral
particl
check
target
transduct
dc
skin
vaccinationsit
drain
ln
matur
transduc
dc
skin
vaccin
sitedrain
ln
induct
expans
specif
ctl
vaccin
sitedrain
ln
peripher
blood
necessari
monitor
techniqu
develop
context
previou
clinic
studi
immunomodul
melanoma
sln
studi
would
provid
vital
confirm
vaccin
behav
way
patient
observ
preclin
model
thu
provid
clinic
proofofconcept
could
move
forward
establish
clinic
efficaci
extend
phaseiii
trial
final
decad
preclin
develop
clinic
translat
ad
vaccin
seem
within
reach
although
thought
reach
point
mani
twist
turn
road
past
differ
ad
configur
experiment
model
help
refin
strengthen
conceptu
basi
applic
current
twocompon
configur
alway
translat
scienc
led
us
back
back
clinic
door
schemat
represent
mode
action
adbas
vaccin
langerhan
cell
lc
dermal
dc
recruit
dermi
vector
deliv
lead
select
higheffici
situ
transduct
dermal
locat
migratori
dc
roughli
three
differ
target
configur
distinguish
twocompon
configur
consist
bispecif
adaptor
fusion
protein
bind
fiber
knob
solubl
car
scar
antiknob
mab
recombin
sequenc
incorpor
fiber
knob
recombin
mosaic
viru
consist
carbind
ablat
wt
fiber
chimer
fiber
incorpor
sequenc
transduct
simultan
activ
lc
dermal
dc
ad
result
matur
migrat
skin
drain
lymph
node
follow
present
endogen
process
transgen
tumorassoci
antigen
context
mhc
molecul
cell
necessari
costimulatori
signal
induc
effect
activ
expans
tumor
antigenspecif
cytotox
cell
vivo
vector
gener
genet
modif
fiber
schemat
represent
wildtyp
trimer
fiber
structur
compris
ntermin
tail
central
shaft
globular
knob
b
structur
bacteriophag
fibritin
protein
contain
central
helic
domain
trimer
domain
ctermin
motif
trimer
fuse
cterminu
artifici
fiber
c
chimer
fiber
protein
compris
ligand
box
highlight
sourc
truncat
part
wildtyp
fiber
bacteriophag
fibritin
use
gener
chimer
fiber
protein
tail
fiber
anchor
chimera
ad
virion
fragment
fibritin
protein
provid
trimer
molecul
mediat
bind
receptor
long
wind
road
lab
clinic
timelin
highlight
gener
preclin
evalu
adenovir
cancer
vaccin
bispecif
antibodi
conjug
gener
chemic
conjug
fab
fragment
neutral
antifiberknob
monoclon
antibodi
mab
agonist
mab
effici
human
monocytederiv
dc
transduct
induct
matur
ad
demonstr
use
bispecif
ab
conjug
use
similar
chemic
conjug
improv
efficaci
ex
vivo
gener
bone
marrowderiv
dc
vaccin
human
papillomavirusinduc
tumor
cell
murin
model
demonstr
abil
ad
select
transduc
activ
dermal
locat
dc
situ
ensur
migrat
enhanc
antigen
specif
cell
prime
abil
demonstr
use
human
skin
explant
model
second
gener
conjug
consist
singl
chain
fv
fragment
fuse
either
solubl
car
fiber
knob
scfv
develop
abil
second
gener
conjug
enhanc
gene
transfer
dc
vitro
improv
cell
activ
capac
demonstr
genet
target
mosaic
ad
vector
direct
cell
gener
effici
transduct
activ
dc
human
skin
explant
demonstr
effort
translat
configur
clinic
ceaencod
colon
cancer
vaccin
came
halt
nih
biolog
resourc
branch
oversight
committe
deem
product
process
composit
result
mosaic
fiber
ad
vector
uncontrol
unpredict
construct
vivo
biodistribut
analysi
third
gener
adaptor
fusion
protein
consist
scar
trimer
tnflike
activ
domain
efficaci
recombin
ad
vaccin
induc
antigenspecif
cell
antibodi
respons
studi
canin
model
use
third
gener
adaptor
protein
select
transduct
matur
dc
human
lymph
node
superior
induct
highavid
melanomareact
cytotox
cell
demonstr
demonstr
vivo
target
dc
skin
ln
induct
efficaci
antitumor
immun
therapeut
set
use
third
gener
adaptor
mous
melanoma
model
